A local health care provider and payer in the U.K, NHS Salford, has failed to reverse a positive draft guidance from the U.K. cost watchdog, the National Institute for Health and Clinical Excellence (NICE), on Boehringer Ingelheim GMBH's new oral anticoagulant, Pradaxa (dabigatran etexilate). In final NICE guidance issued March 15, the drug is recommended as an option for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
NHS Salford's appeal against a positive recommendation by NICE is believed to be the first by a U.K
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?